609 research outputs found

    Expression of toll-like receptor 2 and 4 is increased in the respiratory epithelial cells of chronic idiopathic interstitial pneumonia patients

    Get PDF
    SummaryBackgroundIdiopathic interstitial pneumonia (IIP) is characterized by chronic interstitial inflammation and fibrosis. Although mounting evidence has suggested that toll-like receptor (TLR) 2 and TLR4 are involved in the pathogenesis of non-infectious lung injury in vitro and in mouse models, their roles in human IIP remain unknown.MethodsTo address this issue, we investigated the expression patterns of TLR2 and TLR4 by immunohistochemistry in resected lung tissues from patients with usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP).ResultsType II pneumocytes, bronchial epithelial cells (BECs), and alveolar macrophages accounted for the majority of TLR2- and TLR4-expressing cells in both UIP and NSIP. The numbers of TLR2 and TLR4-positive respiratory epithelial (RE) cells, including type II pneumocytes and BECs, were significantly greater in UIP and NSIP than in the control. In particular, the numbers of TLR2-positive RE cells were much greater in UIP than in NSIP. The intensities of TLR2 and TLR4 expression in type II pneumocytes were also significantly stronger in UIP and NSIP than in the control. A comparison of the TLR expression patterns between the fibroblastic and fibrotic areas in UIP indicated that the numbers TLR2 and TLR4-positive RE cells were similar in fibroblastic areas, whereas the TLR2-positive RE cells outnumbered the TLR4-positive RE cells in the fibrotic areas.ConclusionsThis study demonstrates that RE cells over-express TLR2 and TLR4 in the lungs of IIP patients. These findings suggest that high expression of TLRs may contribute to the pathogenesis of human IIP

    Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells

    Get PDF
    Background: In breast cancer, the HER2/neu oncoprotein, which belongs to the epidermal growth factor receptor family, may trigger activation of the phosphoinositide-3 kinase (PI3K)/Akt pathway, which controls cell proliferation, survival, migration, and invasion. In this study, we examined the question of whether or not adenine nucleotide translocase 2 (ANT2) short hairpin RNA (shRNA)-mediated down-regulation of HER2/neu and inhibitory effects on the PI3K/Akt signaling pathway suppressed migration and invasiveness of breast cancer cells. Methods: We utilized an ANT2 vector-based RNA interference approach to inhibition of ANT2 expression, and the HER2/neu-overexpressing human breast cancer cell line, SK-BR3, was used throughout the study. Results: In this study, ANT2 shRNA decreased HER2/neu protein levels by promoting degradation of HER2/neu protein through dissociation from heat shock protein 90 (HSP90). As a result, ANT2 shRNA induced inhibitory effects on the PI3K/Akt signaling pathway. Inhibition of PI3K/Akt signaling by ANT2 shRNA caused down-regulation of membrane-type 1 matrix metalloproteinase (MT1-MMP) and vascular endothelial growth factor (VEGF) expression, decreased matrix metalloproteinase 2 (MMP2) and MMP9 activity, and suppressed migration and invasion of breast cancer cells. Conclusions: These results indicate that knock-down of ANT2 by shRNA down-regulates HER2/neu through suppression of HSP90`s function and inhibits the PI3K/Akt signaling pathway, resulting ultimately in suppressed migration and invasion of breast cancer cells.Wang S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-81MAHMUT Y, 2009, CANC METASTASIS REV, V28, P15Jang JY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1857Ono M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078-0432.CCR-06-0646Stirling PC, 2006, NAT STRUCT MOL BIOL, V13, P865, DOI 10.1038/nsmb1153Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-06-1554ERIC I, 2006, AM J PHYSIOL-CELL PH, V291, P579Romond EH, 2005, NEW ENGL J MED, V353, P1673Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5Meares GP, 2004, FEBS LETT, V574, P181, DOI 10.1016/j.febslet.2004.08.026Sreedhar AS, 2004, FEBS LETT, V562, P11Citri A, 2004, CELL CYCLE, V3, P51Luciakova K, 2003, J BIOL CHEM, V278, P30624, DOI 10.1074/jbc.M303530200Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121Val JFF, 2002, CANCER GENET CYTOGEN, V138, P69GARCIARUIZ C, 2002, J BIOL CHEM, V277, P16396Slamon DJ, 2001, NEW ENGL J MED, V344, P783Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11Braun S, 2001, CANCER RES, V61, P1890Xu WP, 2001, J BIOL CHEM, V276, P3702Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884Clynes RA, 2000, NAT MED, V6, P443Zhou BP, 2000, J BIOL CHEM, V275, P8027Menard S, 2000, J CELL PHYSIOL, V182, P150Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639Pegram MD, 1998, J CLIN ONCOL, V16, P2659Fiore C, 1998, BIOCHIMIE, V80, P137WOLFGANG HS, 1998, J CELL BIOL, V143, P901Werb Z, 1997, CELL, V91, P439Baselga J, 1996, J CLIN ONCOL, V14, P737CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170HANEMAAIJER R, 1993, BIOCHEM J, V296, P803UNEMORI EN, 1990, J BIOL CHEM, V265, P445MIGNATTI P, 1989, J CELL BIOL, V108, P671SLAMON DJ, 1987, SCIENCE, V235, P177

    Oligonol Ameliorates CCl 4

    Get PDF
    Oxidative stress is thought to be a key risk factor in the development of hepatic diseases. Blocking or retarding the reactions of oxidation and the inflammatory process by antioxidants could be a promising therapeutic intervention for prevention or treatment of liver injuries. Oligonol is a low molecular weight polyphenol containing catechin-type monomers and oligomers derived from lychee fruit. In this study, we investigated the anti-inflammatory effect of oligonol on carbon tetrachloride- (CCl4-) induced acute hepatic injury in rats. Oral administration of oligonol (10 or 50 mg/kg) reduced CCl4-induced abnormalities in liver histology and serum AST and serum ALT levels. Oligonol treatment attenuated the CCl4-induced production of inflammatory mediators, including TNF-α, IL-1β, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) mRNA levels. Western blot analysis showed that oligonol suppressed proinflammatory nuclear factor-kappa B (NF-κB) p65 activation, phosphorylation of extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinases (MAPKs) as well as Akt. Oligonol exhibited strong antioxidative activity in vitro and in vivo, and hepatoprotective activity against t-butyl hydroperoxide-induced HepG2 cells. Taken together, oligonol showed antioxidative and anti-inflammatory effects in CCl4-intoxicated rats by inhibiting oxidative stress and NF-κB activation via blockade of the activation of upstream kinases including MAPKs and Akt

    Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization

    Get PDF
    Background : Tumor-associated macrophages (TAM) play an important role in tumor microenvironment. Particularly, M2 macrophages contribute to tumor progression, depending on the expression of NF-κB. Tumor-derived exosomes can modulate tumor microenvironment by transferring miRNAs to immune cells. Epigallocatechin gallate (EGCG) has well known anti-tumor effects; however, no data are available on the influence of EGCG on communication with cancer cells and TAM. Methods : Murine breast cancer cell lines, 4T1, was used for in vivo and ex vivo studies. Exosome was extracted from EGCG-treated 4T1 cells, and the change of miRNAs was screened using microarray. Tumor cells or TAM isolated from murine tumor graft were incubated with exosomes derived from EGCG-treated and/or miR-16 inhibitor-transfected 4T1 cells. Chemokines for monocytes (CSF-1 and CCL-2), cytokines both with high (IL-6 and TGF-β) and low (TNF-α) expression in M2 macrophages, and molecules in NF-κB pathway (IKKα and Iκ-B) were evaluated by RT-qPCR or western blot. Results : EGCG suppressed tumor growth in murine breast cancer model, which was associated with decreased TAM and M2 macrophage infiltration. Expression of chemokine for monocytes (CSF-1 and CCL-2) were low in tumor cells from EGCG-treated mice, and cytokines of TAM was skewed from M2- into M1-like phenotype by EGCG as evidenced by decreased IL-6 and TGF-β and increased TNF-α. Ex vivo incubation of isolated tumor cells with EGCG inhibited the CSF-1 and CCL-2 expression. Ex vivo incubation of TAM with exosomes from EGCG-treated 4T1 cells led to IKKα suppression and concomitant I-κB accumulation; increase of IL-6 and TGF-β; and, decrease of TNF-α. EGCG up-regulated miR-16 in 4T1 cells and in the exosomes. Treatment of tumor cells or TAM with exosomes derived from EGCG-treated and miR-16-knock-downed 4T1 cells restored the above effects on chemokines, cytokines, and NF-κB pathway elicited by EGCG-treated exosomes. Conclusions : Our data demonstrate that EGCG up-regulates miR-16 in tumor cells, which can be transferred to TAM via exosomes and inhibits TAM infiltration and M2 polarization. We suggest a novel mechanism by which EGCG exerts anti-tumor activity via regulation of TAM in tumor microenvironment.This work was supported by the Global Core Research Center (GCRC) grant (No. 2012–0001190) from the National Research Foundation (NRF), Ministry of Education, Science and Technology (MEST) (Republic of Korea).Peer Reviewe

    Radiation Exposure to Physicians During Interventional Pain Procedures

    Get PDF
    BACKGROUND: Fluoroscopy has been an integral part of modern interventional pain management. Yet fluoroscopy can be associated with risks for the patients and clinicians unless it is managed with appropriate understanding, skill and vigilance. Therefore, this study was designed to determine the amount of radiation received by a primary operator and an assistant during interventional pain procedures that involve the use of fluoroscopy 0aMETHODS: In order to examine the amount of radiation, the physicians were monitored by having them wear three thermoluminescent badges during each single procedure, with one under a lead apron, one under the apron collar and one on the leg during each single procedure. The data obtained from each thermoluminescent badge was reviewed from September 2008 to November 2008 and the annual radiation exposure was subsequently calculated. 0aRESULTS: A total of 505 interventional procedures were performed with C-arm fluoroscopy during three months. The results of this study revealed that the annual radiation exposure was relatively low for both the operator and assistant. 0aCONCLUSION: With proper precautions, the use of fluoroscopy during interventional pain procedures is a safe practiceope

    The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1

    Get PDF
    Gemcitabine is used to treat several cancers including lung cancer. However, tumor cells often escape gemcitabine-induced cell death via various mechanisms, which include modulating bcl-2 family members and NF-κB activation. We previously reported that the C-terminal region of Bfl-1 fused with GFP (BC) is sufficient to induce apoptosis in 293T cells. In the present study, we investigated the anti-tumor effect of combined BC gene therapy and gemcitabine chemotherapy in vitro and in vivo using non-small cell lung cancer cell lines and a xenograft model. Cell lines were resistant to low dose gemcitabine (4-40 ng/ml), which induced NF-κB activation and concomitant up-regulation of Bfl-1 (an NF-κB-regulated anti-apoptotic protein). BC induced the apoptosis of A549 and H157 cells with caspase-3 activation. Furthermore, co-treatment with BC and low dose gemcitabine synergistically and efficiently induced mitochondria-mediated apoptosis in these cells. When administered alone or with low dose gemcitabine, BC suppressed NF-κB activity, inhibited the nuclear translocation of p65/relA, and down-regulated Bfl-1 expression. Furthermore, direct suppression of Bfl-1 by RNA interference sensitized cells to gemcitabine-induced cell death, suggesting that Bfl-1 importantly regulates lung cancer cell sensitivity to gemcitabine. BC and gemcitabine co-treatment also showed a strong anti-tumor effect in a nude mouse/A549 xenograft model. These results suggest that lung cancer cells become resistant to gemcitabine via NF-κB activation and the subsequent overexpression of Bfl-1, and that BC, which has both pro-apoptotic and NF-κB inhibitory effects, could be harnessed as a gene therapy to complement gemcitabine chemotherapy in non-small cell lung cancer

    Kaposi Sarcoma Herpes Virus-associated Hemophagocytic Syndrome Complicated by Multicentric Castleman Disease and Kaposi Sarcoma in a HIV-negative Immunocompetent Patient: An Autopsy Case

    Get PDF
    Kaposi sarcoma herpes virus (KSHV), also known as human herpesvirus-8, plays an important role in the pathogenesis of Kaposi sarcoma (KS), multicentric Castleman disease (MCD) of the plasma cell type, and primary effusion lymphoma. KSHV is rarely associated with the hemophagocytic syndrome (HPS), but when it does occur, it most occurs in immunocompromised patients. We report herein an unusual case of KSHV-associated HPS in an immunocompetent patient. A previously healthy 62-yr-old male was referred for evaluation of leukocytopenia and multiple lymphadenopathies. After a lymph node biopsy, he was diagnosed with MCD of the plasma cell type. KSHV DNA was detected in the lymph node tissue by polymerase chain reaction. Following a short-term response of the leukocytopenia to prednisolone, mental change, left side weakness, fever, thrombocytopenia, hemolytic anemia, and renal failure developed. Despite intravenous immunoglobulin therapy and plasmapheresis, he expired. The lymph nodes were infiltrated by hemophagocytic histiocytes in the sinuses. Pulmonary nodules and gastric erosions were shown to be KS. KSHV DNA was detected in the stomach, lung, and liver. This is the first case of multiple KSHV associated diseases including MCD and KS with KSHV-associated hemophagocytic syndrome in an HIV-negative, non-transplant, immunocompetent patient

    악성림프종에서 SV40 Large T Antigen의 검색

    Get PDF
    Background : The association of simian virus 40 (SV40) with certain types of human cancers, including malignant lymphomas, has been a topic of interest for some time. Although the virus is distributed worldwide, its incidences vary according to the specific types of tumors, and the epidemiological areas. The aim of this study was to investigate the frequency of SV40 in malignant lymphomas among Korean patients. Methods : One hundred seventy three cases of malignant lymphomas were evaluated by immunohistochemical staining for SV40 large T antigen (TAg), using an extremely sensitive, tyramide based, catalyzed signal amplification method. Results: From 158 non-Hodgkin`s lymphomas, including 115 diffuse large B-cell lymphomas, and 15 Hodgkin`s lymphomas, none of the cases were positive for SV40 TAg. Conclusions : SV40 does not appear to be related to the pathogenesis of malignant lymphomas among Koreans.Amara K, 2007, INT J CANCER, V121, P2693, DOI 10.1002/ijc.23038Lee HS, 2007, CLIN CANCER RES, V13, P4154, DOI 10.1158/1078-0432.CCR-07-0173Shah KV, 2007, INT J CANCER, V120, P215, DOI 10.1002/ijc.22425Vilchez RA, 2006, HUM PATHOL, V37, P1130, DOI 10.1016/j.humpath.2006.04.020Doerries K, 2006, ADV EXP MED BIOL, V577, P102Vilchez RA, 2005, VIROLOGY, V342, P38, DOI 10.1016/j.virol.2005.06.053Paik JH, 2005, HISTOPATHOLOGY, V47, P281, DOI 10.1111/j.1365-2559.2005.02222.xSui LF, 2005, PATHOLOGY, V37, P157, DOI 10.1080/00313020500058474Heinsohn S, 2005, HAEMATOLOGICA, V90, P94VILCHEZ RA, 2005, HAEMATOLOGICA, V90, P6Jin M, 2004, J MED VIROL, V74, P668Brousset P, 2004, INT J CANCER, V112, P533, DOI 10.1002/IJC.20397Barbanti-Brodano G, 2004, VIROLOGY, V318, P1, DOI 10.1016/j.virol.2003.09.004Nakatsuka S, 2003, CANCER RES, V63, P7606MacKenzie J, 2003, J NATL CANCER I, V95, P1001Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S002-9343(03)0087-1Chang MS, 2003, J PATHOL, V199, P447, DOI 10.1002/path.1302Vivaldi A, 2003, J CLIN ENDOCR METAB, V88, P892, DOI 10.1210/jc.2002-020436STRATTON K, 2003, IMMUNIZATION SAFETYVilchez RA, 2002, LANCET, V359, P817Shivapurkar N, 2002, LANCET, V359, P851JAFFE E, 2001, PATHOLOGY GENETICS TMartini F, 1998, INT J CANCER, V78, P669NUMA F, 1995, CANCER RES, V55, P4676GLUZMAN Y, 1981, CELL, V23, P175ONEILL FJ, 1981, VIROLOGY, V112, P800FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713
    corecore